Streetbeat News

Analyst Ratings

AMGN

Amgen (NASDAQ:AMGN) has received mixed analyst ratings over the past three months, with a recent positive shift in average price targets. Analysts have varied in their recommendations, with some raising and others lowering their price targets. Amgen's financial performance shows strong net margins and ROE, but challenges in debt management.

Portfolio Pulse from Benzinga Insights

September 25, 2024 | 6:01 pm

VRNT

Analysts have provided mixed ratings for Verint Systems (NASDAQ:VRNT) over the past three months, with a majority being bullish. The average 12-month price target has decreased by 4.6% to $35.71. Analysts have adjusted their ratings and price targets, reflecting varied expectations for Verint's market performance.

Portfolio Pulse from Benzinga Insights

September 25, 2024 | 6:01 pm

AAPL

Over the past three months, 49 analysts have evaluated Apple (NASDAQ:AAPL), with a range of opinions from bullish to bearish. The average 12-month price target for Apple has increased by 6.1% to $250.8. Analysts have maintained or raised their ratings, with some setting high price targets up to $300. Apple's financials show strong profitability and growth, but concerns about its debt-to-equity ratio remain.

Portfolio Pulse from Benzinga Insights

September 25, 2024 | 6:01 pm

FA

Citigroup analyst Peter Christiansen maintains a Neutral rating on First Advantage (NASDAQ:FA) but raises the price target from $19 to $21.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 6:00 pm

ADP

Citigroup analyst Peter Christiansen maintains a Neutral rating on Automatic Data Processing (ADP) but raises the price target from $260 to $295.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 5:58 pm

VKTX

Oppenheimer analyst Jay Olson has reiterated an Outperform rating for Viking Therapeutics (NASDAQ:VKTX) and maintained a price target of $138.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 5:50 pm

TME

Morgan Stanley has downgraded Tencent Music Entertainment Group (NYSE:TME) from Overweight to Equal-Weight and reduced the price target from $15 to $13.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 5:48 pm

MRVL

Marvell Technology (NASDAQ:MRVL) has seen unusual options activity with a bearish sentiment from financial giants. Despite this, analysts maintain positive ratings with target prices ranging from $90 to $120. The stock is currently trading at $70.85, down 0.49%.

Portfolio Pulse from Benzinga Insights

September 25, 2024 | 5:46 pm

NSC

Evercore ISI Group has maintained an 'Outperform' rating on Norfolk Southern and raised its price target from $265 to $276, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 5:43 pm

HRTX

Needham analyst Serge Belanger has reiterated a Buy rating on Heron Therapeutics (NASDAQ:HRTX) and maintained a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 5:42 pm